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ReviewThe Ubiquitin Proteasome System in
Neurodegenerative Diseases:
Sometimes the Chicken, Sometimes the Egg
sponse, and neurodegeneration. While inactivation of a
major enzyme, such as E1, is obviously lethal, mutations
in enzymes or in recognition motifs in substrates that
do not affect vital pathways or that affect the involved
process only partially result in a broad array of pheno-
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Technion-Israel Institute of Technology types. Likewise, acquired changes in the activity of the
system can also evolve into certain pathologies. TheHaifa 31096
Israel pathological states associated with the ubiquitin system
can be generally classified into two groups: (1) those2 Section for Neuronal Survival
Wallenberg Neuroscience Center that result from loss of function—mutations in a ubiquitin
system enzyme or target substrate that result in stabili-Biomedical Center (BMC)
Department of Physiological Sciences zation of certain proteins, and (2) those that result from
gain of function—abnormal or accelerated degradationLund University
S-221 84 Lund of the protein target. Recent findings have linked aberra-
tions in the ubiquitin system to neurodegenerative disor-Sweden
ders. In some cases, such as mutations in the ubiquitin
ligase Parkin that results in Autosomal Recessive Juve-
nile Parkinsonism (AR-JP), the pathogenetic linkage be-The ubiquitin-proteasome system targets numerous
cellular proteins for degradation. In addition, modifica- tween the aberration in the system and the resulting
disease is direct (the egg, according to one view). Intions by ubiquitin-like proteins as well as proteins con-
taining ubiquitin-interacting and -associated motifs many other cases, however, it appears that the aggre-
gated, disease-specific proteins that characterize manymodulate many others. This tightly controlled process
involves multiple specific and general enzymes of the of these disorders inhibit the activity of the UPS. Here,
inhibition of the system may play a secondary role insystem as well as many modifying and ancillary pro-
teins. Thus, it is not surprising that ubiquitin-mediated the pathogenetic process (the chicken). In addition to
Parkinson’s disease, this review discusses Alzheimer’sdegradation/processing/modification regulates a broad
array of basic cellular processes. Moreover, aberra- disease, Prion diseases, familial amyotrophic lateral
sclerosis (ALS) with mutations in the SOD1 gene, andtions in the system have been implicated, either as
a primary cause or secondary consequence, in the polyglutamine expansion disorders. In each case, the
potential role of the UPS is critically discussed, with anpathogenesis of both inherited and acquired neurode-
generative diseases. Recent findings indicate that the emphasis given to whether the observed changes are
primary or whether they are secondary phenomena re-system is involved in the pathogenesis of Parkinson’s,
Alzheimer’s, Huntington’s, and Prion diseases as well sulting from another underlying cause.
as amyotrophic lateral sclerosis. This raises hopes for
a better understanding of the pathogenetic mecha- The Ubiquitin-Proteasome Pathway
nisms involved in these diseases and for the develop- Degradation of a protein via the ubiquitin-proteasome
ment of novel, mechanism-based therapeutic modal- pathway involves two discrete and successive steps:
ities. (1) tagging of the substrate by covalent attachment of
multiple ubiquitin molecules to synthesize the polyubi-
Introduction quitin chain proteolytic signal and (2) degradation of the
Degradation of intracellular proteins via the ubiquitin- tagged protein by the 26S proteasome complex with
proteasome system (UPS) is a highly complex, tempo- release of free and reusable ubiquitin catalyzed by ubi-
rally controlled, and tightly regulated process that plays quitin-recycling enzymes (DUBs; for a scheme of the
major roles in a variety of basic cellular processes. Tar- ubiquitin system, see Figure 1).
geting of protein to degradation via the UPS involves Conjugation of ubiquitin, a highly evolutionarily con-
two discrete and successive steps: (1) conjugation of served 76 residue polypeptide, to the protein substrate
multiple ubiquitin moieties to the substrate to generate proceeds via a three-step cascade mechanism. Initially,
the polyubiquitin degradation signal and (2) destruction the ubiquitin-activating enzyme E1 activates ubiquitin
of the tagged protein by the downstream 26S protea- in an ATP-requiring reaction to generate a high-energy
some complex with release of free and reusable ubiqui- thiol ester intermediate, E1-Subiquitin, where ubiquitin
tin, a reaction catalyzed by deubiquitinating enzymes is bound to an internal E1 Cys residue. One of several
(DUBs). With the multitude of substrates targeted and E2 enzymes (ubiquitin-carrier proteins or Ubiquitin-Con-
the myriad processes involved, it is not surprising that jugating enzymes [UBCs]) transfers the activated ubiqui-
aberrations in the pathway have been implicated in the tin moiety from E1, via an additional high-energy thiol
pathogenesis of many diseases, including certain malig- ester intermediate, E2-Subiquitin, to the substrate that
nancies, disorders of the immune and inflammatory re- is specifically bound to an E3, a member of the ubiquitin-
protein ligase family of proteins. Several distinct families
of E3 enzymes have been described. For the Homolo-*Correspondence: c_tzachy@netvision.net.il (A.C.), patrik.brundin@
neurol.lu.se (P.B.) gous to the E6-AP C Terminus (HECT) domain E3s, the
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gated ubiquitin molecule, a polyubiquitin chain is syn-
thesized. The degradation signal that is recognized by
the 26S proteasome complex is made of a Lys48 polyu-
biquitin chain. Conjugation to other Lys residues, Lys63
for example, serves nonproteolytic functions of the sys-
tem, such as activation of transcription.
It appears that E3s play a key role in the ubiquitin-
mediated proteolytic cascade since they serve as the
specific substrate recognition factors of the system. Ap-
proximately 1000 different E3s have been identified in
the human genome, based on specific, commonly
shared structural motifs, such as the RING finger. In
some cases, proteins are modified by a single ubiquitin
moiety. In many of these cases, the modification leads
to targeting of the tagged substrate for degradation in
the lysosome/vacuole. It should be noted that modifica-
tion by a single ubiquitin moiety is catalyzed via an
identical mechanism and set of enzymes to those that
catalyze polyubiquitination. In some other cases, the
first ubiquitin moiety is conjugated to the substrate by
one E3, while chain elongation is catalyzed by a different
ligase, often termed E4.
Degradation of polyubiquitinated substrates is carried
out by a large protease complex, the 26S proteasome
that does not generally recognize nonmodified sub-
strates. In one established and exceptional case, how-
ever, that of the polyamine synthesizing enzyme orni-
thine decarboxylase (ODC), the proteasome recognizes
Figure 1. The Ubiquitin-Proteasome System
and degrades the substrate following its association
Ubiquitin is first activated by the ubiquitin-activating enzyme E1, to
with another protein, antizyme, without prior ubiquitina-a high-energy thiol ester intermediate. It is then transferred, still as
tion. The proteasome is a large, multicatalytic proteasea high-energy intermediate, to a member of the ubiquitin-carrier
that degrades polyubiquitinated proteins to small pep-proteins family of enzymes, E2 (known also as a ubiquitin-conjugat-
ing enzyme [UBC]). From E2, it can be transferred directly to the tides. It is composed of two subcomplexes: a 20S core
substrate that is bound specifically to a member of the ubiquitin particle (CP) that carries out the catalytic activity and a
ligase family of proteins, E3 (A). This occurs when the E3 belongs regulatory 19S regulatory particle (RP). The 20S CP is
to the RING finger family of ligases. In the case of an Homologous a barrel-shaped structure composed of four stackedto the E6-AP C Terminus (HECT) domain-containing ligase (B), the
rings: two identical outer  rings and two identical inneractivated ubiquitin moiety is transferred first to the E3, to generate
 rings. The eukaryotic  and  rings are each composedyet another high-energy thiol ester intermediate, before it is trans-
of seven distinct subunits, giving the 20S complex theferred to the E3-bound target substrate. Additional ubiquitin moie-
ties are added successively to the previously conjugated one in a general structure of 1-71-71-71-7. The catalytic sites are
similar mechanism to generate a polyubiquitin chain. The polyubi- localized to some of the  subunits. The population of
quitinated substrate binds specifically to the 26S proteasome com- proteasomes in any given cell may be heterogeneous.
plex: the substrate is degraded to short peptides, and free and
Most of the 20S complexes are capped by two 19Sreusable ubiquitin is released via the activity of deubiquitinating en-
complexes, one on each extremity; however, they mayzymes.
have a 19S subcomplex on one side and a different
complex, e.g., PA28, on the other. This polar organiza-
ubiquitin is transferred once again from the E2 enzyme tion can secure unidirectionality in the flow of sub-
to an active site Cys residue on the E3 to generate strates, and also, according to certain studies, genera-
a third high-energy thiol ester intermediate, ubiquitin- tion of preferred peptide products such as antigenic
SE3, prior to its transfer to the ligase bound substrate. epitopes that are trimmed properly to fit recognition by
On the other hand, RING finger-containing E3s catalyze, the MHC class I molecules and the cytotoxic T cell.
most probably, direct transfer of the activated ubiquitin One important function of the 19S RP is to recognize
moiety from E2 to the E3 bound substrate. Members of ubiquitinated proteins and other potential substrates of
other families of E3s, such as the U-Box- or PHD domain- the proteasome. Two ubiquitin binding subunits of the
containing ligases, act most probably in a similar manner 19S RP have been identified, Rpn10 (S5a in mammalian
to that of the RING finger ligases. E3s catalyze the last cells) and Rpt5 (S6); however, their essential role and
step in the conjugation process: covalent attachment mode of action have not been discerned. A second func-
of ubiquitin to the substrate. The first ubiquitin moiety tion of the 19S RP is to open an orifice in the  ring
is generally transferred to an -NH2 group of an internal that will allow entry of the substrate into the proteolytic
Lys residue in the substrate to generate a covalent iso- chamber. Also, since a folded protein would not be able
peptide bond. In some cases, however, it is conjugated to fit through the narrow proteasomal channel, it is as-
linearly to the free NH2 group at the N-terminal residue. sumed that the 19S particle unfolds substrates and in-
By successively adding additional activated ubiquitin serts them into the 20S CP. Both the channel opening
function and the unfolding of the substrate require meta-moieties to internal Lys residues on the previously conju-
Review
429
bolic energy, and indeed, the 19S RP contains six differ- sors, and transcriptional activators and their inhibitors.
Cell surface receptors and ER proteins are also targetedent ATPase subunits. Following degradation of the sub-
strate, short peptides are released along with free and by the system. Finally, mutated and denatured/mis-
folded proteins are recognized specifically and are re-reusable ubiquitin. The peptides are further degraded
by cytosolic amino- and carboxypeptidases, although moved efficiently. In this capacity, the UPS plays a key
role in the cellular quality control and defense mecha-a small fraction of them are transported across the endo-
plasmic reticulum (ER) membrane, bind to MHC class I nisms.
The UPS can be regulated at the level of ubiquitinationmolecules, and are presented to cytoxic T cells. Protea-
somal degradation does not always generate peptides. or at the level of proteasome activity. Since conjugation
and proteasomal degradation are required for numerousIn some cases, the proteasome processes the ubiquiti-
nated substrate precisely, releasing a truncated prod- cellular functions, regulation must be delicately and spe-
cifically tuned. In a few cases, general rather than spe-uct. In the case of the NF-B transcriptional regulator,
active subunits are generated from longer inactive pre- cific components of the system can be modulated by
physiological signals. For example, upregulation of thecursors.
In spite of the major progress that has been made in pathway is observed during massive degradation of
skeletal muscle proteins that occurs under normal fast-elucidating the mode of action of the UPS, major prob-
lems have remained unsolved. For example, how does ing but also under pathological conditions such as can-
cer-induced cachexia, severe sepsis, metabolic acido-the system achieve its high specificity and selectivity?
Why are certain proteins extremely stable in the cell, sis, or following denervation. In most cases, however,
regulation is specific, and the target substrates are rec-while others are extremely short-lived? Why are certain
proteins degraded only at a particular time point during ognized by specific ligases that bind to defined motifs.
The targeting motif can be a single amino acid residuethe cell cycle or only following specific extracellular
stimuli, yet are stable under most other conditions? It (e.g., the N-terminal residue), a sequence (the Destruc-
tion box in cyclins), or a domain (a hydrophobic patch,appears that specificity of the ubiquitin system is deter-
mined by two distinct and unrelated groups of proteins: for example) that is not normally exposed. In other
cases, the motif is generated posttranslationally, e.g.,(1) E3s and (2) ancillary proteins. First, within the ubiqui-
tin system, substrates must be specifically recognized phosphorylation that occurs in response to external sig-
nals. Phosphorylation can occur either on the substrateby an appropriate E3 as a prerequisite for their ubiquiti-
nation. In most cases, substrates are not recognized in or the ligase. The phosphorylated site in the substrate
can serve as the ligase-anchoring motif [such as thea constitutive manner, and in some cases, they are not
recognized directly by the E3. In many cases, the sub- phosphorylated domain—DS32(P)GLDS36(P)—in IB that
serves to bind the TrCP ligase]. As for phosphorylationstrate must undergo a certain change, e.g., posttransla-
tional modification such as phosphorylation, that ren- of the ligase, it is not known whether it activates the
enzyme to a form that now recognizes the substrate(s)ders it susceptible for recognition. In some instances,
the E3 must be “switched on” by undergoing posttrans- or whether it is involved directly in substrate recogni-
tion/binding.lational modification in order to yield an active form
that recognizes the substrate. The stability of additional Both enzymes and substrates of the ubiquitin system
have been found to be modified by UBiquitin-Like (UBL)proteins depends on association with ancillary proteins,
such as molecular chaperones, that act as recognition proteins. Modification by UBLs occurs only once. In the
case of enzymes, modification affects their activity. Forelements in trans and serve as a link to the appropriate
ligase. Others, such as certain transcription factors, example, modification of the Cullin component of the
SCF E3 complexes by the ubiquitin-like protein NEDD8have to dissociate from the specific DNA sequence to
which they bind in order to be recognized by the system. increases the affinity of the ligases to the E2 component
of the conjugation machinery. Skp1, Cullin, F-Box pro-Stability of yet other proteins depends on hetero- or
homooligomerization: only the monomers are degraded. teins (SCFs) are ubiquitin ligase complexes composed
of shared, common components (Skp1, Cullin, and alsoThus, in addition to the E3s themselves, modifying en-
zymes (such as kinases), ancillary proteins, or DNA se- a RING finger protein) and a unique, substrate-recogniz-
ing F-Box protein. They are mostly involved in the recog-quences to which substrates bind also play an important
role in the recognition process. nition of phosphorylated substrates. In the case of sub-
strates, modification can affect their availability to theUbiquitin-mediated proteolysis of a variety of cellular
proteins plays an important role in many basic cellular ubiquitination/degradation machinery and, consequently,
their cellular stability. For example, in the case of IB,processes. Among these are regulation of cell cycle and
division, differentiation and development, involvement the inhibitor of the transcriptional regulator NF-B, mod-
ification by SUMO-1 was shown to protect the substratein the cellular response to stress and extracellular ef-
fectors, morphogenesis of neuronal networks, modula- from ubiquitination. In a completely different case,
SUMOylation of RanGAP1 is necessary for targeting oftion of cell surface receptors, ion channels and the se-
cretory pathway, DNA repair, transcriptional regulation, the protein to its subcellular destination in the nuclear
pore complex. Modification by UBLs requires E1, E2,transcriptional silencing, long-term memory, circadian
rhythms, regulation of the immune and inflammatory and possibly an E3 that use a similar catalytic mecha-
nism to that used by the enzymes that catalyze ubiquiti-responses, and biogenesis of organelles. The list of cel-
lular proteins that are targeted by ubiquitin is growing nation. Yet, they are different enzymes, and the two sets
are not interchangeable.rapidly. Among them are cell cycle regulators such as
cyclins, cyclin-dependent kinase inhibitors and proteins A recently discovered group of proteins are those that
carry a UBL domain, such as the ubiquitin ligase Parkin,involved in sister chromatid separation, tumor suppres-
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and proteins that have a Ubiquitin Interacting Motif (UIM) inhibit the ubiquitin system (Bence et al., 2001). Yet,
an emerging concept is that the sequestration of theor a UBiquitin-Associated (UBA) domain. The UBL do-
main that is part of other proteins cannot be conjugated, aggregated proteins from the cytosol and nucleoplasm
and their concentration in defined inclusion bodies sep-as it lacks a free, C-terminal Arg-Gly-Gly domain. The
UBL domain in these proteins serves, most probably, arates them from sensitive cellular machineries, such as
transcriptional apparati. Therefore, the inclusion bodiesto facilitate interaction with other ubiquitin binding pro-
teins of the system, such as the proteasome. This inter- may be protective, and it is the soluble fraction of the
aggregated proteins that is toxic. In any event, the ap-action may enhance the efficiency of the proteolytic
process by bringing together different components of pearance of the inclusion bodies that contain the aggre-
gated, disease-specific proteins has emerged as a com-the system. The UIM- and UBA-containing proteins
serve, most probably, as recognition elements in trans, mon but poorly understood mechanistic theme in
neurodegenerative disorders.binding ubiquitinated proteins and linking them to other
elements of the system. Thus, Rad23 and Dsk2 in yeast
are believed to bind polyubiquitinated substrates in the Parkinson’s Disease
cytosol and target them to the proteasome. Again, such The case of PD highlights the complexity of the involve-
linking elements may increase the efficiency of the pro- ment of the UPS in the pathogenesis of neurodegenera-
teolytic process. tion. In PD, the main neuropathological feature is the
(For recent reviews on ubiquitination, the proteasome, progressive death of neurons in the substantia nigra
and ubiquitin-like proteins, see Adams, 2003; Di Fiore pars compacta with resulting loss of dopaminergic in-
et al., 2003; Glickman and Ciechanover, 2002; Hilt and nervation of the striatum. This causes a gradual develop-
Wolf, 2000; Joazeiro and Weissman, 2000; Pickart, 2001; ment of akinesia, rigidity, and tremor. In the vast majority
Verger et al., 2003; Voges et al., 1999; Weissman, 2001). of patients, some of the remaining nigral dopaminergic
neurons exhibit aggregated proteins in the form of cyto-
plasmic LB inclusions. Several apparently independentThe Ubiquitin System and Pathogenesis
of Neurodegeneration aberrations linked to defects in the UPS have been de-
scribed in various rare forms of hereditary PD. TheseAccumulation of ubiquitin conjugates and/or inclusion
bodies associated with ubiquitin, proteasome, and cer- rare cases shed light on basic pathogenetic mecha-
nisms that maybe relevant also to the most prevalent,tain disease-characteristic proteins have been reported
in a broad array of chronic neurodegenerative diseases, late-onset and sporadic cases of PD (for a recent review
on the subject, see Giasson and Lee, 2003).such as the neurofibrillary tangles of Alzheimer’s dis-
ease (AD), brainstem Lewy bodies (LBs) (the neuropath- Parkin Mutations in Autosomal-Recessive
Parkinson’s Diseaseological hallmark in Parkinson’s disease [PD]), Bunina
bodies in Amyotrophic Lateral Sclerosis (ALS), and nu- An important player in the pathogenesis of PD is Parkin
(PARK2). Parkin is a 465 amino acid residue, 52 kDaclear inclusions in CAG repeat expansion (polygluta-
mine/Q extension) disorders such as Huntington’s dis- protein with a UBL domain at the N-terminal region and
two RING finger motifs at the carboxy-terminal region.ease, Spinocerebellar Ataxias (SCAs), and Spinal and
Bulbar Muscular Atrophy (SBMA; Kennedy’s disease) Various deletion and point mutations in the gene have
been found in50% of patients with AR-JP (known also(reviewed recently by Alves-Rodrigues et al., 1998; Sher-
man and Goldberg, 2001) (Figure 2). As discussed later, as Autosomal Recessive Parkinson’s Disease [ARPD]),
one of the most common familial forms of PD (Kitadaa direct linkage between an aberration in the ubiquitin
system and the resulting pathology has been estab- et al., 1998). Interestingly, with a few exceptions, AR-
JP is characterized by a lack of LBs. Later studies havelished in certain rare cases of PD or AD. However, in
most cases, and especially in the sporadic, late-onset identified Parkin as a ubiquitin-protein ligase that acts
along with the ubiquitin-conjugating enzymes UbcH7diseases, such a direct linkage does not appear to exist.
One factor that complicates the foundation of such a and UbcH8 (Imai et al., 2000; Shimura et al., 2001). The
RING finger domain is involved, most probably, in re-link is the realization that many of these diseases, e.g.,
AD and PD, can no longer be considered etiopathologi- cruitment of the E2 component of the ubiquitination
machinery, while the UBL can serve as a proteasomecal entities, but rather syndromes with different etiolo-
gies. In these cases, accumulation of ubiquitin conju- binding motif (Upadhya and Hegde, 2003), thus facilitat-
ing transfer of the polyubiquitinated substrate(s) to thegates in LBs may be secondary and reflect failed
attempts by the UPS to remove the damaged/abnormal degrading machinery. Indeed, it has been reported that
Parkin associates with the RPN10 (S5a) subunit of theproteins. While the initial hypothesis was that inclusion
bodies are generated because of the inherent tendency 26S proteasome (Sakata et al., 2003). The binding to the
proteasome may facilitate transfer of the conjugates toof the abnormal proteins to associate with one another
and aggregate, it is now thought that the process may be the proteolytic machinery. Interestingly, mutation at R42
abrogates the binding of Parkin to the proteasome, sug-more complex and involves active cellular machineries,
such as generation of specific reversible aggregate con- gesting that it can cause AR-JP. Recent findings have
demonstrated that Parkin is a component of an SCF-centrates (aggresomes) (Johnston et al., 1998) or move-
ment of the proteasome to specific subcellular sites like E3 complex along with the F-box/WD repeat protein
hSel-10 and Cullin 1 (Staropoli et al., 2003). This finding,where proteolysis of abnormal proteins may occur (Fa-
bunmi et al., 2000). The pathogenetic significance of if further corroborated, has far reaching implications.
From this study, it appears that Parkin serves as a com-these aggregates has remained enigmatic. Recent find-
ings demonstrate that soluble aggregated proteins can mon, RING finger-containing component shared by a
Review
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Figure 2. The UPS and Pathogenesis of Neurodegeneration
The figure describes four different aspects related to protein misfolding and neurodegenerative diseases; all are discussed in the text. (1)
Triggers that can cause the accumulation of misfolded proteins—these include both mutations and epigenetic factors. (2) The primary
responses to accumulating misfolded proteins—these are related to the reduced capacity of the UPS that is the consequence of protein
overload/inhibition by aggregated substrates. The misfolded proteins that accumulate may be refolded by chaperones or accumulate in
aggregates in the cytoplasm, nucleus, or extracellular space. The aggregates may sequester additional proteins (3) Types of neuropathological
extracellular and intracellular protein deposits that can be found in the central nervous system of patients with PD, AD, Prion disease, ALS,
and polyglutamine (PolyQ) disorders. Finally, (4) four secondary disease targets, i.e., the different cell functions that are affected by the protein
conformational disease. In different protein conformation disorders, it has been shown that gene transcription can be markedly disturbed at
the levels of histone regulation and individual transcription factors. There is evidence for disrupted axonal transport of different cell constituents.
At the presynaptic level, neurotransmitter synthesis can be impaired; vesicular storage is sometimes disrupted; proteins involved in vesicle
cycling are altered. At the postsynaptic level, the misfolded proteins can change receptor densities and downstream signaling transduction
pathways. Finally, the diseases can cause neuronal death by several mechanisms, including impairment of mitochondrial function and
mitochondrial release of cytochrome c with subsequent caspase activation. It has also been suggested that aberrant protein folding can lead
to pore formation in cell membranes and loss of ionic homeostasis. For details and references, see the text.
group of putative, yet to be discovered, SCF-like com- substrate binding subunits (for known/putative Parkin
substrates, see below). Most of the point mutationsplexes (similar to the RING finger protein Rbx1/Hrt1/
Roc1 in the SCFTrCP, SCFSkp2, and VBC [von Hippel Lin- described in Parkin reside in its RING-IBR-(In Between-
RINGS)-RING domain and result in its inactivation (Luck-dau, Elongin B and C] ligase complexes). It is the hSel-
10 component in this particular complex that is involved ing et al., 2000). Like all other known RING finger-con-
taining ligases, Parkin has an autoubiquitinating activity.in specific substrate recognition. According to this hy-
pothesis, it is possible that other SCF complexes that An interesting finding is that not all mutations found in
Parkin in AR-JP patients are inactivating mutations (see,contain Parkin recognize their different substrates via
specific, yet to be identified F-box proteins or other for example, Chung et al., 2001; Corti et al., 2003; Imai
Neuron
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et al., 2001). It is possible that the mutations only reduce in regulating synaptic vesicle dynamics, and its accumu-
lation in patients with a mutation in Parkin perturbs thethe activity of the enzyme (the autocatalytic one and/or
the one displayed toward the exogenous substrates). process. A second important substrate of Parkin is the
Parkin-associated endothelial-like (Pael) receptor, a pu-Alternatively, other mechanisms, such as interaction of
the E3 with essential partners, are affected by the muta- tative G protein-coupled transmembrane polypeptide
(Imai et al., 2001). When overexpressed in cells, thetions. Such a partner can be, for example, the cochaper-
one CHIP (Carboxy terminus of the Hsc70-Interacting receptor becomes misfolded. It then aggregates, and
the insoluble protein elicits cell death via the UnfoldedProtein) that was found to increase the activity of Parkin,
possibly by acting as an E4 (Imai et al., 2002) or the Protein Response (UPR). The UPR is a mechanism that
involves a stress response in the ER, including increasedproteasome (see above). In this respect, it should be
mentioned that not only recessive loss of Parkin consti- biosynthesis of ER chaperones, in response to accumu-
lation of misfolded/denatured/mutated proteins in thistutes a risk factor in AR-JP, but haploinsufficiency has
been also suggested to cause the disease in some cases organelle (for a recent review on UPR, see Kaufman,
2002). Parkin ubiquitinates and promotes the degrada-(West et al., 2002). Thus, it appears that a decrease in
enzyme activity rather than its complete absence can tion of the insoluble Pael receptor, acting in this reaction
along Ubc6 and Ubc7, two E2s located in the ER. Impor-underlie the pathogenesis of AR-JP related to Parkin
mutations. It is also possible that the mutated allele tantly, the insoluble Pael receptor accumulates in the
brains of patients with AR-JP. Overexpression of Parkinhas a dominant effect. In this scenario, it codes for a
dominant-negative enzyme that binds the substrate and can rescue cells from the UPR elicited by a variety of
stresses, such as exposure to H2O2, DNA alkylatingsequesters it but cannot ubiquitinate it, which results in
its stabilization. Some of the enigmas regarding Parkin agents, short-wavelength UV light, high osmolarity, and
heat shock (Imai et al., 2000). Specifically, it can protectfunction could have been resolved by the generation
of Parkin null mutant mice. However, the phenotype dopaminergic cells in D. melanogaster from neurotoxic-
ity induced by overexpressed Pael receptor (Yang etdescribed in the first published report on such knockout
mice has complicated the state of affairs rather than al., 2003). Of note is that overexpression of Parkin also
suppresses -synuclein (SYN) toxicity, suggesting thatsimplifying it (Goldberg et al., 2003). The mice display
increased extracellular concentrations of dopamine in Parkin may play a role in regulating this protein as well
(see below). Importantly, the insoluble form of Pael accu-the striatum and reduced synaptic excitability in the
striatal target neurons. The resulting behavioral syn- mulates in the brains of AR-JP patients that have a
mutated Parkin. Another substrate of Parkin is a noveldrome includes deficits in motor coordination and
somatosensory function. Quite contrary to the expecta- 22 kDa form of O-glycosylated SYN (Sp22) (Shimura
et al., 2001). It is important to note that while mutationstions, the mice do not exhibit a reduction in dopaminer-
gic neurons in the substantia nigra, and the steady-state in the nonglycosylated 14 kDa form of SYN have been
linked to the pathogenesis of PD (see below), to date,levels of CDCrel-1, synphilin-1, and -synuclein—three
putative substrates of Parkin (see below)—appear to be they have not been linked with Parkin-associated AR-
JP. SinceSp22 accumulates in a nonubiquitinated formnormal. It is hard to reconcile these data with what we
currently know regarding Parkin, its substrates, and the in the brains of AR-JP patients, it is postulated that this
accumulation can be toxic. It should be noted, however,mutations found in AR-JP patients. It is possible that
Parkin is partially redundant in the mouse, and another that the finding of accumulation of this new form of
modified SYN in PD patients has to be further corrobo-E3 can catalyze some but not all of the reactions cata-
lyzed by Parkin. On the other hand, Parkin appears to rated, along with elucidation of the possible role the
modification plays in the pathogenetic process. Parkinhave a role in synaptic transmission that has not been
described previously and that was not possible to ob- also ubiquitinates Synphilin-1, a protein of hitherto un-
known function that contains a coiled-coiled domainserve in patients.
A crucially important development in our understand- and an ATP/GTP binding motif and that associates with
SYN (Chung et al., 2001). Overexpression of Synphi-ing of Parkin function is the identification of its exoge-
nous native cellular substrates. The overriding hypothe- lin-1 with SYN results in the formation of protein inclu-
sions, yet the function of Synphilin in this process assis is that a defect in Parkin will result in accumulation
of this protein(s), which is toxic to the dopaminergic well as the role of its ubiquitination are still elusive. Since
inclusion bodies are lacking in most cases of AR-JP, itneurons. Several substrates have been identified that
are ubiquitinated by Parkin, yet it is not clear whether is possible that the ubiquitination of Synphilin by wild-
type Parkin plays a role in their formation, by targetingit is the accumulation of one or several of these proteins
that underlies the pathogenesis of this familial form of ubiquitinated Synphilin to these bodies and removing it
from the cytosol where it can be toxic. An interestingPD. One of these substrates is Cell Division Control
related protein (CDCrel-1) (Zhang et al., 2000), an 44 finding relates to the role of Parkin in the elimination of
proteins containing an expanded polyglutamine stretch.kDa member of the septin family of proteins that includes
GTPases required for cytokinesis. CDCrel-1 has been Overexpression of Parkin reduced the accumulation of
Ataxin-3-derived, polyglutamine-containing fragmentimplicated in the inhibition of exocytosis through its
interactions with syntaxin. A large fraction of it is bound (Tsai et al., 2003). Concomitantly, it reduced the inhibi-
tion of the proteasome and the activation of caspase 12to synaptic vesicles. Following transfection to a cell line,
wild-type CDCrel-1 inhibits secretion of growth hor- that are induced by accumulation of the polyglutamine-
containing fragment. The affinity of the polyglutaminemone, while the dominant-negative species increases
secretion (Beites et al., 1999). It is possible that CDCrel-1 fragment to Parkin was increased by Hsp70, in agree-
ment with the hypothesis that molecular chaperonesis involved in regulating transmitter release via its role
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may play a role in the recruitment of misfolded proteins against an additional stress, such as occurs during ac-
cumulation of aggregated proteins, the Pael receptor,to the conjugation machinery (see, for example, Berco-
vich et al., 1997). A rather surprising, recently discovered for example. Importantly, the finding that most AR-JP
patients do not display LBs supports a few interestingsubstrate of Parkin is cyclin E (Staropoli et al., 2003)
that is ubiquitinated by the SCF complex that contains assumptions. First, these inclusions may not play a role
in promoting the pathogenetic process. Second, oneParkin. Consistent with the notion that cyclin E is tar-
geted by the Parkin ligase complex is the finding that can argue that ubiquitination of proteins may play a role
in their aggregation and precipitation and result in theParkin deficiency leads to accumulation of cyclin E in
cultured postmitotic neurons exposed to the gluta- formation of inclusions, as LBs are not formed in the
absence of ubiquitinated proteins. Further supportingmatergic excitotoxin kainite and promotes their apopto-
sis. Overexpression of Parkin is reported to attenuate this hypothesis is the finding of Cummings and collabo-
rators (Cummings et al., 1999) that inactivation of thecyclin E accumulation and rescue the cells from apopto-
sis. While cyclin E can still be a substrate for Parkin, it gene coding for the E6-AP (Ube3a) ligase in a transgenic
model of SCA-1 resulted in a reduced number of neuronsis not clear whether its accumulation plays a direct role
in cell toxicity. Another recently described substrate of containing intranuclear aggregates (see below). In con-
clusion, the discovery of Parkin, elucidation of its roleParkin is the p38 subunit of the aminoacyl-tRNA synthe-
tase complex (Corti et al., 2003). Overexpression of p38 as a ubiquitin ligase, identification of certain protein
substrates that are targeted by the ligase, and the find-in cells resulted in a formation of aggresome-like in-
clusions which sequestered Parkin. In the dopamine- ing that many of mutations found in Parkin in AR-JP
patients inactivate its ubiquitin ligating activity or possi-producing neuroblastoma cell line SH-SY5Y, Parkin
rescued the cells from p38-induced cell death. An inter- ble association with its partners are of utmost impor-
tance and may provide keys to the enigmatic puzzle ofesting point is that the mutated Parkin species K161N,
which is associated with AR-JP, could still ubiquitinate PD pathogenesis (for recent reviews on Parkin and its
possible involvement in the pathogenesis of PD, seep38, suggesting that it is not loss of function that under-
lies the human disease (see above). Finally, Synaptotag- Dawson and Dawson, 2003; Dev et al., 2003b; McNaught
and Jenner, 2001; Mizuno et al., 2001).min XI has also recently been reported to be a substrate
of Parkin (Huynh et al., 2003). It is possible that ubiquiti- Mutations in Ubiquitin Carboxy-Terminal
Hydrolase-L1 Can Cause Parkinson’s Diseasenation of this substrate affects synaptic vesicle trans-
port and/or transmitter release. Recent findings in a German family with PD have re-
vealed a mutation in the gene coding for the ubiquitinParkin has been reported also to associate with actin
filaments but not with microtubules (Huynh et al., 2000). carboxy-terminal hydrolase UCH-L1 (Leroy et al., 1998).
While the mutation did not lead to complete inactivationIt has not been demonstrated, however, to modify actin.
Yet, it is possible that the ligase regulates actin activity of the enzyme, the hydrolase was clearly less active
compared to its wild-type counterpart. The simple ex-by ubiquitinating an actin-associated protein, which in
turn affects the function of actin and thereby influences planation is that the mutation leads to a shortage in free
ubiquitin that should have been recycled from conju-the movement of synaptic vesicles. Detailed study of
Drosophila parkin null mutant revealed reduced life gates, which results in general impairment of the func-
tion of the UPS. This impairment leads, in turn, to accu-span, locomotor disorders (in flight and climbing), and
selective male sterility (Greene et al., 2003). Only a sub- mulation of certain proteins that may be toxic to
neurons. Interestingly, inactivation of UCH-L1 in miceset of dopaminergic neurons was affected. The disor-
ders in locomotion were caused initially by disruption does not lead to dopaminergic neuronal death but to
Gracile Axonal Dystrophy (GAD) syndrome. This is ain muscle integrity that later evolved into cell death.
Sterility was caused by a late defect in spermatogenesis, recessive autosomal disease that results in sensory
ataxia at an early stage, followed by motor ataxia at aoccurring at the individualization stage. Importantly, the
earliest defect observed in both muscles and sperma- later stage (Saigoh et al., 1999). The GAD mice display
axonal degeneration in the gracile tract of the spinaltids was mitochondrial dysfunction—displayed by swell-
ing and disintegration of matrix and cristae. Thus, while cord and medulla oblongata but not cell death in the
substantia nigra. The mutation in UCH-L1 that was foundthe parkin dysfunction syndromes in the fly and human
appear to be distinct, they may share a similar basic linked to PD was identified as I93M. It should be noted
that the mutation was not identified via gene linkagepathogenetic mechanism—aberration in mitochondrial
function. studies but rather through a gene association study.
Although the causative relationship between the muta-In summary, recent findings regarding Parkin clearly
point toward different direct etiological roles that this tion and the disease appears to be strong, it is neverthe-
less circumstantial at this stage. Since the mutation isenzyme may have in the pathogenesis of AR-JP. As
noted, however, it is not clear whether the collective not 100% penetrant and since the GAD mice do not
display a Parkinsonian syndrome—neither clinically noraccumulation of all of its substrates—the known and
those left to be discovered—is toxic to the dopaminergic histopathologically—it is not clear whether loss of the
ubiquitin hydrolytic activity underlies the entire pathol-cells or if there is one protein in particular that is toxic.
It is also unclear why catecholaminergic neurons of the ogy observed in patients with the I93M mutation. There-
fore, it was suggested that, in addition to the loss of thesubstantia nigra and locus ceruleus are selectively vul-
nerable to the loss of Parkin in AR-JP patients. It is ubiquitin hydrolytic activity, additional factor(s) may be
involved in the pathogenetic process involved in PD. Itpossible that the high oxidative state associated with
cathecolamine biosynthesis does not leave a large has been reported recently that while the monomeric
form of UCH-L1 catalyzes deubiquitination, the dimersenough reserve of defense mechanisms to protect
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display a ubiquitin ligase activity that generates ubiqui- wild-type protein was shown to be a major component of
tin-K63 bonds (Liu et al., 2002). Mono- and diubiquiti- LBs and Lewy neurites in sporadic PD, dementia with
nated SYN were polyubiquitinated by the enzyme, sug- LBs (DLB), and the LB variant of AD. SYN fibrils also
gesting that it acts as an E4 (Koegl et al., 1999). constitute the central core of oligodendroglial (in con-
Incidentally, UCH-L1 and SYN colocalize with synaptic trast to neurons in all other diseases) inclusion filaments
vesicles and can be coimmunoprecipitated (Liu et al., in multiple system atrophy (MSA) (Gai et al., 2003). The
2002). The ligase activity was diminished significantly autosomal-dominant nature of the disease associated
in a S18Y mutant of UCH-L1. Interestingly, mutation in with mutant SYN strongly suggests that a gain as op-
this site is a polymorphic variant that protects the carrier posed to a loss of function underlies the disease mecha-
population from PD (Satoh and Kuroda, 2001). Thus, it nism. Overexpression of wild-type, but in particular mu-
is possible that the activity of the ligase plays also a tant SYN in many cell types but not in all, induces
pathogenetic role in the UCH-L1 I93M hydrolase muta- apoptosis or sensitizes the cells to toxic agents, includ-
tion, as a decreased activity of the hydrolase may result ing proteasome inhibitors (see, for example, Lee et al.,
in a net increased activity of the ligase. Supporting this 2001a). While direct connection between Parkin and
notion is the finding that inactivation of the ligase is SYN has not been established, overexpression of wild-
protective. It should be noted, however, that the physio- type Parkin can rescue cultured catecholaminergic pri-
logical role of the conjugating activity as well as the mary mesencephalic neurons from the toxic effects of
function of the mono-, di-, and polyubiquitinated SYNs SYN (Petrucelli et al., 2002), suggesting that the two
have remained elusive. In particular, the pathogenetic proteins share a common pathway involved in cell death.
role of polyubiquitinated Lys63 SYN is not known. One, Why is SYN oligomerization toxic? As noted above,
although unlikely, possibility is that the ligase activity it is still debatable whether LBs that sequester the aggre-
depletes the free pool of ubiquitin that cannot be replen- gated proteins are toxic or protective. From recent stud-
ished by the mutated hydrolase. Alternatively, the Lys63 ies in several neurodegenerative disease models, in-
polyubiquitin chains of SYN that cannot be trimmed/ cluding PD, SCA, and HD, it appears that it is the soluble,
removed by the mutated hydrolase accumulate and are oligomeric forms of the disease-characteristic proteins
toxic to the cells. Since many of the ubiquitin recycling (SYN in the case of PD, ataxins in the case of SCAs,
enzymes have redundant function, it was important to and Huntingtin in the case of HD) that are responsible
find whether the activity of UCH-L1 is complemented for their toxicity (for SYN, see, for example, Petrucelli
by another ubiquitin hydrolytic enzyme. An interesting et al., 2002; Xu et al., 2002). The linkage between SYN
candidate is UCH-L3. Mice homozygous for a targeted and the UPS system is not that clear. AR-JP is character-
deletion of the UCH-L3 gene are indistinguishable from ized by lack of LBs and SYN aggregates. On the other
the wt animals (Kurihara et al., 2001). However, mice hand, it is not clear whether polyubiquitination of SYN
homozygous for both UCH-L1 and UCH-L3 deletions is necessary for its degradation. It has been shown that
die early due to dysphagia and display degeneration the protein is targeted by the proteasome (Bennett et
of the nucleus tractus solitarius and area postrema in al., 1999) and that the mutant form is slightly less sus-
addition to the degeneration of the gracile tract that is ceptible, but it is not clear whether aberrations in this
observed in GAD mice that only have a UCH-L1 deletion. process play a role in the pathogenesis of PD. It is
Interestingly, mutant UCH-L3 was found in a modifier possible, although it has not been shown yet, that modi-
screen for ataxin-1-interacting proteins in Drosophila as fication by ubiquitin leads to aggregation and precipita-
an enhancer of the SCA-1 phenotype (Fernandez-Funez tion of the protein and that the unmodified protein is
et al., 2000). more soluble. The suggestion that the glycosylated form
Autosomal-Dominant Parkinson’s Disease of SYN is targeted by Parkin (Shimura et al., 2001) may
Caused by Mutations in -Synuclein resolve part of the enigma. Accordingly, it is plausible
A third important player that links aberrations in the UPS
that the accumulation of this, otherwise normally de-
to the pathogenesis of PD is SYN (PARK1). SYN is a
gradable, form of SYN is toxic. Therefore, patients with
small, 140 amino acid residue protein that is thought
AR-JP—who cannot degrade it because of the mutationto regulate/participate in dopamine neurotransmission/
in the Parkin E3 (see above)—develop neurodegenera-release via effects on vesicular storage. Wild-type SYN
tion. However, this model does not explainSYN toxicityis monomeric, but at high concentration, it oligomerizes
in most sporadic PD patients who have a functional andto -pleated sheets known as protofibrils. Structural
active Parkin and SYN (as noted, mutated SYNs andanalysis reveals that the protofibrils are made of 10–12
Parkin were found only in rare cases of familial PD).nm fibrils. The protofibrils can further aggregate and
An important finding, however, in that respect is thatprecipitate as amyloid fibrils that are present in Lewy
aggregated and even monomeric SYN bind to the S6bodies, the hallmark of sporadic, late-onset PD. The
proteasome subunit and inhibit proteasomal functionfunction of SYN is also impaired in familial forms of
(Snyder et al., 2003). Thus, aggregation, which is thePD where mutant SYN is found. In the late 1990s, it was
primary event, may lead to secondary damage by inhib-reported that two mutations in the N-terminal domain of
iting the UPS (Bence et al., 2001). It is also possible thatSYN, A30P (Kruger et al., 1998) and A53T (Polymero-
polyubiquitination of SYN itself is not relevant at all topoulos et al., 1997), were associated with a rare form
the pathogenesis of PD. Instead, impairment of SYNof autosomal-dominant familial PD. This caused a major
function may disturb ubiquitination of SYN-associatedshift of attention within the research field to the role of
proteins, such as Synphilin (Chung et al., 2001) andprotein misfolding in the pathogenesis of PD (reviewed
tyrosine hydroxylase (Doskeland and Flatmark, 2002),recently in Dev et al., 2003a). The mutant proteins have
a higher tendency to generate protofibrils. In parallel, the and thereby perturb neuronal homeostasis.
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The DJ-1 Gene Is a New Player to all these diseases has been proposed by several
in Parkinson’s Disease authors. These models suggests that proteolytic stress
Recently discovered mutations in the DJ-1 gene have with an accompanying defect in protein handling is cru-
also been associated with AR-JP (Bonifati et al., 2003). cial and that the substantia nigra neurons are particularly
The function of the DJ-1 protein is not known, but it is vulnerable due to their high content of dopamine (sum-
supposed to be involved in oxygen sensing, acting as marized in Lotharius and Brundin, 2002; McNaught and
an antioxidant, probably protecting/rescuing other pro- Olanow, 2003). The increased vulnerability of dopamin-
teins from oxidative damage. DJ-1 activity may be regu- ergic neurons may be due to a high basal rate of protein
lated by SUMOylation, as it was found that it binds to oxidation which is due to the enzymatic and autooxida-
the SUMO E3 PIASx (Takahashi et al., 2001). Interest- tion machineries involved in dopamine oxidation. This,
ingly, one of the DJ-1 mutations that is associated with along with low steady-state levels of the 19S/PA700 and
AR-JP is a point mutation, L166P. Miller and colleagues PA28 regulators of the proteasome may render these
(Miller et al., 2003) have recently shown that this muta- cells more susceptible to proteolytic stress than other
tion destabilizes DJ-1 via promotion of its rapid, UPS- brain cells.
mediated degradation. Initial data show that the mutated
protein is active, and it is its rapid degradation that leads Alzheimer’s Disease and Related Tauopathies
to loss of function of the protein that may underlie the In AD, the dominant symptom is dementia, initially char-
pathogenesis of AR-JP in this case. Thus, in this case, acterized by a loss of short-term memory which gradu-
the UPS may contribute to PD pathogenesis by remov- ally develops into a loss of most higher faculties. In
ing a mutated yet active protein that is recognized more 1906, Alois Alzheimer was the first to describe neuro-
efficiently by the system compared to its wild-type coun- pathological changes involving protein aggregates and,
terpart. This case may be analogous to the loss of func- much ahead of his time and unknowingly, he introduced
tion observed during the rapid degradation of mutated neuropathologists to the field of aberrant protein fold-
F508 Cystic Fibrosis Transmembrane conductance ing—before it had even been discovered! Patients with
Regulator (CFTR), which is also an active protein, and AD display two types of protein deposits: extracellular
that the rapid degradation of which contributes to the amyloid plaques and intracellular neurofibrillary tangles
pathogenesis of cystic fibrosis (CF) in patients carrying (Hardy and Selkoe, 2002). The latter neuropathological
the mutation. It should be noted that CFTR degradation change is also observed in a series of other neurological
is mediated by Endoplasmic Reticulum Associated conditions that have been collectively named tauopa-
Degradation (ERAD—a quality control mechanism that thies and include some forms of Parkinsonism, Pick’s
eliminates, via the UPS, misfolded/mutated/abnormal disease, and boxing-induced dementia (Dementia pugi-
membrane or lumenal ER proteins following their retro- listica) (Lee et al., 2001b).
translocation to the cytosol via the Sec61 translocation The plaques in AD are rich in amyloid  peptides (A)
channel). For a recent review on ERAD, see (Kostova that are produced by proteolytic cleavage of the amyloid
and Wolf, 2003). precursor peptide (APP), a glycolipid located in the outer
The Role of the Ubiquitin Proteasome System
cell membrane. Three different proteases, called , ,
in Sporadic Parkinson’s Disease
and  secretases, can cleave APP at specific sites and
Along with an age-related tendency to accumulate oxi-
generate products that are well characterized. Concomi-
dized damaged proteins, failure of the UPS to ade-
tant cleavage of APP by  and  secretase at specificquately remove misfolded/abnormal proteins may un-
sites can result in fragments (A140 or A142) thatderlie the degeneration of nigral cells also in sporadic
can misfold and form extracellular fibrils. These fibrilsPD (McNaught and Olanow, 2003), which constitutes
are around 6–12 nm long and consist of  sheets. It isthe most common form of the disease. It has been re-
debated whether the fibrils are toxic through formationported that  but not  subunits of the core catalytic
of pores (Caughy and Lansbury, 2003) (Figure 2) or20S subcomplex of the 26S proteasome are lost
whether the extracellular amyloid deposits that they can(McNaught et al., 2002), and 20S proteasomal enzymatic
form are the main culprits. In contrast, the neurofibrillaryactivities are impaired in the substantia nigra in sporadic
tangles are intracellular and are rich in tau, a structuralPD (McNaught and Jenner, 2001). The 19S/PA700 pro-
protein that is normally associated with microtubuli. Inteasome activator was also decreased, and the levels
conjunction with the formation of neurofibrillary tangles,of the PA28 regulator were almost undetectable in
the synthesis of the tau protein increases, and it under-the substantia nigra compared to other brain areas
goes an abnormal posttranslational modification char-(McNaught et al., 2003). However, it is not clear why
acterized by hyperphosphorylation. Proteolytic pro-these changes were so striking in nigral tissue samples
cessing/degradation of tau is also believed to bethat contained many more cells than those actually af-
important for the formation of the neurofibrillary tangles,fected by neuronal death in PD. In any event, one should
although the molecular pathways involved in this pro-be careful in the interpretation of these data, as it is not
cess are not fully understood. Mutations in the tau geneclear whether the inhibition of the proteasome indeed
can cause the tauopathy Pick’s disease (mentionedresults in a reduced capacity of the UPS in vivo and, if
above). Mutant tau alone does not cause AD, favoringso, whether the reduction is large enough to inflict dam-
the idea that accumulation of erroneously processed Aage (see also below).
is a key event in AD pathogenesis. Familial cases of ADSo what can one learn from the rare genetic diseases
with an autosomal-dominant inheritance constitute onlythat affect components and substrates of the UPS on the
5% of the cases (Forloni et al., 2002) but have beeninvolvement of the system in the vastly more prevalent
sporadic cases of PD? A common pathogenetic base instructive in unraveling possible pathogenetic mecha-
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nisms involved in the sporadic cases. They have demon- A. However, A has been demonstrated to reduce pro-
teasome activity in reticulocyte lysates (Gregori et al.,strated that AD can be caused by mutations in the APP
gene, either in the vicinity of the secretase cleavage 1995), suggesting that increased levels of the peptide
could underlie the reduction in UPS function observedsites, causing abnormal APP processing, or in the se-
quence coding for A, giving rise to a peptide that is in the AD brain.
Perhaps the most compelling evidence for the involve-more likely to self-aggregate. Finally, some patients ex-
press mutant presenilin proteins 1 and 2 (PS1 and PS2) ment of the UPS in AD pathogenesis comes from one
of the experiments of nature. A transcriptional misread-that can change the processing of APP by altering 
secretase activity, thereby promoting the generation of ing can cause the deletion of two nucleotides in the
mRNA coding for ubiquitin (van Leeuwen et al., 2000).amyloidogenic A (Hardy and Selkoe, 2002).
Is impairment of the UPS involved in the pathogenesis The resulting frameshift mutant form of ubiquitin is
called UBB	1, and it has a 19 amino acid residueof AD? It has been shown that A can be degraded by
the proteasome in cultured neurons and astrocytes, and C-terminal extension. UBB	1 was first identified in neu-
rons of patients with AD and Down’s syndrome (whotreatment with the proteasome inhibitor lactacystin de-
creased viability of cells exposed to A (Lopez Salon et also exhibit AD-like brain pathology when middle-aged)
(van Leeuwen et al., 1998). UBB	1 has also been ob-al., 2003). Postmortem tissue studies have shown an
interesting region-specific reduction in proteasome ac- served at low levels in brains of elderly individuals with
mild cognitive impairment and patients with other neuro-tivity in AD patients (Keller et al., 2000). Thus, brain
regions thought to be particularly involved in the lost degenerative diseases (van Leeuwen et al., 2000) as well
as in Mallory bodies in the liver afflicted by diseasebrain functions (e.g., hippocampus and related limbic
structures and inferior parietal lobe) displayed reduced (French et al., 2001). Due to the absence of the crucial
C-terminal RGG, UBB	1 cannot bind to target proteins.activity, although the levels of the  and  subunits
of the proteasome were not changed. In contrast, the However, it can be ubiquitinated by wild-type ubiquitin—
produced from correctly generated transcripts in theproteasomal activity was normal in the occipital lobe
and cerebellum—regions involved in vision and motor same cell—that can bind to two specific lysine residues
in UBB	1 (Lindsten et al., 2002). The polyubiquitinatedcoordination, functions that are relatively spared in AD.
A recent study confirmed a brain region-specific reduc- UBB	1 cannot be degraded by the proteasome and, by
binding to it, probably inhibits its activity toward othertion in proteasomal activity, with a frontal cortical region
being affected whereas the striatum, occipital, and tem- substrates (De Vrij et al., 2001; Lam et al., 2000). Further-
more, it cannot be deubiquitinated by the ubiquitin recy-poral lobes were spared (Keck et al., 2003). The authors
argue that paired helical filaments present in neurofibril- cling enzymes and, therefore, when present at high lev-
els, causes a “dominant-negative” inhibition of the 26Slary tangles and containing the tau protein are the perpe-
trators. They present evidence that paired helical fila- proteasome both in model cell systems (Hope et al.,
2003; Lam et al., 2000; Lindsten et al., 2002) and inments obtained from AD brain or generated in vitro can
inhibit proteasome function and that in AD brain tissue cultured cells obtained from a transgenic mouse specifi-
cally generated to assay UPS function in vivo (Lindstenthese filaments coimmunoprecipitate with the protea-
et al., 2003). Overexpression of UBB	1 by adenoviralsome (Keck et al., 2003). Other studies in cultured neuro-
transduction in cultured neuroblastoma cells can impairblastoma cells show that unfolded tau is normally de-
the UPS to the extent that they finally undergo apoptosisstroyed by the proteasome without prior ubiquitination,
(De Vrij et al., 2001). In summary, there is little questionand induction of conformational changes in tau by treat-
that high levels of UBB	1 can be detrimental to cellment with SDS prevents its degradation (David et al.,
function. It is unlikely that an increased level of UBB	12002). Finally, there is also evidence for a reduced activ-
is a direct cause of AD because it occurs also in otherity of E1 and E2 enzymes in cerebral cortex samples
neurodegenerative conditions. However, the recent re-from AD patients compared to age-matched controls
ports showing that UBB	1 can inhibit the proteasome(Lopez Salon et al., 2000). Taken together, several lines
suggest that it may contribute to disease pathogenesis.of evidence point to a reduced UPS function in AD and
In summary, the evidence that the UPS plays a pivotalsuggest that both A and tau are important players in
role in the pathogenesis of AD is compelling. The recentthe game. One should be careful, however, in the inter-
unraveling of the fascinating UBB	1 story in AD suggestspretation of these data. It is not clear whether the inhibi-
that we may soon see many more completely noveltion of the proteasome is large enough to inflict damage
pathogenetic mechanisms involved in neurodegenera-(see also above). Also, the observation of proteasome-
tive diseases, and primary failure of the UPS could bedependent, yet ubiquitin-independent degradation of
a key element in several of them.tau clearly requires further corroboration.
So is it the chicken or the egg? That is, does a reduc-
tion in the activity of the UPS lead to a greater tendency Prion Disease
Prion diseases have brought the linkage between abnor-of A to accumulate and generate amyloid plaques, or
do conformational changes in A or tau cause protea- mal protein conformation in its purest form and neurode-
generation to the center stage. This family of diseasessome inhibition? One characteristic of AD is that it shows
a higher prevalence with age. The ability to increase is considered to be caused by a protein component of
the proteinaceous infectious (prion) particles, originallyubiquitin conjugation in response to stressors de-
creases in ageing tissue (Shang et al., 1997). The protea- proposed to be the causative agent of these diseases
by Stanley Pruisner (1982). As discussed later, recentsome activity in the mammalian brain decreases with
increasing age (Keller et al., 2002), suggesting that the studies suggest that failure of the UPS could trigger
prion pathogenesis (Hooper, 2003).aged brain is less able to handle the aberrantly folded
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Human prion diseases include Creutzfeld-Jakob dis- is expressed? The Prion protein normally interacts with
the chaperone BiP and undergoes assisted folding (Jinease, fatal familial insomnia, Gerstmann-Stra¨ussler-
Scheinker disease, and kuru. They can be sporadic et al., 2000). Alternatively, if misfolded, it is believed to
be directed to degradation via ERAD (Yedidia et al.,(80%), inherited (15% of cases have one of over 23
known mutations), or transmitted (5%) (McKintosh et 2001). In a cell culture model, mutant PrP associated
with Gerstmann-Stra¨ussler-Scheinker disease can beal., 2003). This latter feature gives them a unique status
among protein conformational neurological disorders rapidly degraded (half-life
 10 min), possibly even with-
out prior ubiquitination (Zanusso et al., 1999). Followingand hence the name Transmissible Spongiform Enceph-
alopathies (TSEs). In cattle, prions can cause Bovine UPS inhibition with lactacystin, the protein accumulates
and forms aggregates in the ER, Golgi apparatus, andSpongiform Encephalopathy (BSE), called in lay terms
“mad cow disease.” Over the past two decades, this nucleus. In the absence of proteasome inhibition, the
mutant PrP does not form aggregates, suggesting thatdisease has become increasingly common in the Euro-
pean Community due to the inclusion of cow carcasses impairment of UPS may also be involved in pathogenesis
of the human disease (Zanusso et al., 1999).in cattle feed. The demonstration that it can be transmit-
ted to humans, where it causes a special form of a new Recent work has highlighted a novel possible role for
failure of the UPS in initiating prion disease, which canvariant of Creutzfeld-Jakob disease, has compounded
the problem and raised fears of a major outbreak of explain the cause of some cases of sporadic prion dis-
ease. Lindquist and colleagues proposed that inhibitionprion diseases over the next few decades, although
mathematical modeling suggests that such an occur- of UPS, which can be caused by ageing or following a
pharmacological treatment, can lead to accumulationrence is unlikely (McKintosh et al., 2003).
The clinical features of prion diseases in humans vary. of PrPc in the cytoplasm where it is spontaneously con-
verted into a PrPsc-like species because it is not rapidlyThey have in common a progressive development of
severe motor disturbance and dementia leading to death degraded by the UPS (Hooper, 2003; Ma and Lindquist,
2002; Ma et al., 2002). Consequently, the cytosolic PrPsc-within a few months to a few years after diagnosis, which
can be years to decades after the initial infection in like isoform triggers cell death, with subsequent release
of PrPsc-like particles and infection of neighboring cells.transmissible cases. In fatal familial insomnia, the clini-
cal presentation also includes a striking, untreatable Specifically, Lindquist and collaborators have shown
that experimental inhibition of the UPS by proteasomeinability to sleep. Prion disease neuropathology is char-
acterized by widespread neuronal death, accompanied inhibitors can lead to the appearance of PrPsc-like spe-
cies in otherwise normal cultured cells (Ma et al., 2002).by spongiform vacuolation and astrogliosis, usually
combined with widespread deposits of extracellular am- They suggest that the PrPsc is derived from misfolded
PrPc that has been retrotranslocated from the ER to theyloid aggregates. These aggregates contain the caus-
ative agent, i.e., an insoluble form of the prion protein cytoplasm (Ma and Lindquist, 2002) (Figure 2). Once in
the cytoplasm, the PrPc would be efficiently degraded(PrP), which appears in a  sheet secondary structure
and is termed PrP-scrapie (PrPsc). The normal cellular by the UPS via the ERAD pathway, but this does not
occur in the presence of the proteasome inhibitors. Aisoform of PrP is called PrPc, and it is a 33–35 kDa
small fraction of the accumulated PrPc is converted intoprotein made of 209 amino acids with a high content of
the PrPsc-like isoform, initiating the vicious cycle of cell-helical secondary structure. PrPc is abundant in many
death and transmission to neighboring cells. The gener-cells throughout the body, particularly in the immune
ation of PrPsc is suggested to continue even after theand nervous systems, and is typically anchored to the
proteasome inhibitor is removed from the medium, sug-outer cell membrane, where it may act as a copper
gesting that the process is self-perpetuating once it hasbinding protein with antioxidant properties (Brown,
been triggered (Ma and Lindquist, 2002). The research-2002). The conformational change can be transmitted,
ers have found additional support for the cytotoxic ca-i.e., if cells are exposed to PrPsc, the normal PrPc can
pacity of PrPc from experiments with transgenic micebe induced to undergo misfolding. Experiments in
expressing the gene coding for a cytoplasmic form PrPc.knockout mice have demonstrated unequivocally that
The mice gradually develop ataxia and cerebellar degen-development of the disease is dependent upon the pres-
eration and display an insoluble form of prion protein,ence of PrPc, and therefore, transmitted PrPsc cannot
suggesting that they have generated a PrPsc-like isoformexert toxicity in animals that are null mutants for PrPc
(Ma et al., 2002).(Bueler et al., 1993).
The model proposed by Lindquist and collaboratorsThere are three different ways by which PrPsc can
is important as it identifies malfunction of UPS as again access to the brain. First, by transmission through
potentially important player in prion pathogenesis. How-exposure of the cells to PrPsc, either through ingestion
ever, this concept is still controversial. For example,of infected material or by iatrogenic causes (e.g., expo-
Harris and collaborators found no evidence for retro-sure to infected surgical instruments, hormone prepara-
grade translocation of PrPc from the ER to the cyto-tions, or grafted tissues); second, by inheritance of one
plasm. They suggest that the increased production ofof over 30 known mutations in the prion gene; and third,
PrPc in the presence of proteasome inhibitors may re-by spontaneous mutations in the prion gene in a single
flect an increase of gene transcription by the inhibitorcell, with subesquent spread of PrPsc to neighboring
via an effect on its promoter (Drisaldi et al., 2003).cells, as has been suggested to occur in the most com-
mon sporadic forms of prion disease (McKintosh et
al., 2003). Amyotrophic Lateral Sclerosis
There are different forms of amyotrophic lateral sclerosisWhat is the evidence that the UPS may be involved
in the pathogenic processes once a mutant prion protein (ALS), all primarily display widespread death of brain-
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stem and spinal motoneurons, corticospinal degenera- on cell function. Urushitani and coworkers (Urushitani
et al., 2002) showed that mutant SOD1 is degraded bytion, paralysis of skeletal muscle, and eventual neuronal
cell death. Around 5%–10% of all cases of ALS are the UPS in cultured cells and that oxidative damage
increases the degree of ubiquitination of mutant buthereditary, and in 20% of these patients (1%–2% of all
patients), 100 different autosomal-dominant muta- not of wild-type SOD1. They found that the proteasome
catalytic activity was decreased in neuroblastoma cellstions—mostly single amino acid substitutions—have
been identified in the gene coding for Copper-Zinc su- following 1 week of expression of a mutant SOD1 gene.
Accordingly, they proposed that, in familial ALS, oxida-peroxide dismutase (SOD1) (Valentine and Hart, 2003).
There is very little evidence to suggest that alterations tive damage to mutant SOD1 leads to misfolding and
polyubiquitination of the protein and eventually inhibitsin SOD are a common feature of sporadic ALS (Alexan-
der et al., 2002). The normal function of SOD1 is to the UPS. Unlike in some other neurodegenerative dis-
eases, where the misfolded proteins are thought to re-scavenge oxygen radicals and prevent oxidative stress.
Mutations in the SOD1 gene do not induce cell loss by cruit subunits of the proteasome into the aggregates,
there is no evidence for this occurring in the cellularaffecting cellular antioxidant defenses. Rather, mutant
SOD1 may act through one of two different mechanisms model of familial ALS (Urushitani et al., 2002). In an
attempt to understand the preferential death of spinal(Valentine and Hart, 2003). The first is that the mutant
protein promotes oxidative stress through a gain-of- motoneurons in ALS, the investigators examined the
effect of proteasome inhibitors on primary mixed cul-function mechanism where improper handling of copper
may lead to the enzyme catalyzing aberrant pro-oxidant tures derived from embryonic spinal cord. They ob-
served a selective death of the motoneurons in the cul-reactions (Cleveland and Liu, 2000). Alternatively, the
enzyme itself may misfold and generate protein aggre- ture and proposed that these neurons are particularly
sensitive to perturbations of the UPS function (Urushi-gates, thereby implicating a role for the UPS in disease
pathogenesis (Cleveland and Liu, 2000; Julien, 2001; tani et al., 2002). Thus, as a disease model they sug-
gested that continued breakdown of mutant SOD1 even-Valentine and Hart, 2003). The ubiquitinated SOD1-con-
taining aggregates appear as cytosolic, hyaline inclu- tually overloads the UPS in spinal neurons. This leads
to accumulation and aggregation of mutant SOD1 andsions called Bunina bodies (Figure 2), reminiscent of
LBs, in neurons of patients and transgenic rodents car- also to impairment of the defense against oxidative
stress, which is partially dependent upon proper UPSrying disease-related mutations (Bruijn et al., 1998; Kat-
suno et al., 2003; Tu et al., 1996). They also contain function. Consequently, due to the increased stress,
mutant SOD1 will misfold more rapidly. This, in turn, willcomponents of the proteasome and neurofilaments
(Alves-Rodrigues et al., 1998; Johnston et al., 2000). further exacerbate substrate overload on the UPS of the
already sensitive spinal motoneurons, as part of a self-What have laboratory experiments told us about the
interplay between misfolded SOD1 and the UPS? In perpetuating vicious cycle (Urushitani et al., 2002). This
hypothesis, linking misfolding of SOD1 and impairmenttransgenic animals, the aggregates form relatively late
in the disease process (Morrison et al., 1998). Mutant of the UPS to cell death, is conceptually attractive. How-
ever, the support for the idea that aggregates of mutantSOD1 proteins are less soluble than the wild-type pro-
tein (Johnston et al., 2000; Shinder et al., 2001) and SOD1 are toxic is not unanimous. In another recent
study, it was reported that expression of mutant SOD1sediment more readily in vitro (Okado-Matsumoto et al.,
2000). The mutant SOD1 proteins, unlike the wild-type in PC12 cells increases formation of aggregates and that
aggregate formation is further enhanced by oxidativeform, are degraded by the UPS (Hoffman et al., 1996;
Johnston et al., 2000). In transgenic cells, mutant SOD1 stress and experimental inhibition of UPS (Lee et al.,
2002). However, contrary to the hypothesis that the ag-generates nonnative oligomers, and the subsequent in-
hibition of the UPS increases the tendency for the pro- gregates per se are toxic—e.g., by causing functional
UPS inhibition—the mutant SOD1 aggregates did nottein to form aggresomes (Johnston et al., 2000). Overex-
pression of the chaperone HSP70 has been found to kill cells (Lee et al., 2002). Two recent studies have dem-
onstrated that cells expressing mutant SOD1 may bereduce aggregate formation and death in nonneuronal
cultured cells expressing mutant SOD1 (Bruening et al., particularly vulnerable to additional inhibition of the pro-
teasome. Thus, exposure to lactacystin resulted in in-1999). Similarly, overexpression of the putative SOD1
E3 ligase dorfin can inhibit cell death induced by the creased cell death in human cell lines expressing mutant
SOD1 (Aquilano et al., 2003; Hyun et al., 2003). In onemutant protein (Niwa et al., 2002), presumably by pro-
moting its removal via the UPS. Interestingly, dorfin ex- model, the treatment led also to increased nitric oxide
production and protein nitration, and inhibition of nitricpression is increased in the spinal cord of ALS patients
(Ishigaki et al., 2002), which may suggest that the ex- oxide synthase both reduced aggregate formation and
cell death (Hyun et al., 2003). In the other model, thepression of the E3 ligase is increased in an attempt to
enhance clearance of the mutant SOD1. The E3 enzyme expression of mutant SOD1 alone was sufficient to in-
duce oxidative stress, giving rise to increased protea-is also enriched in aggregates observed in PD and ALS
(Hishikawa et al., 2003). Spinal cords from sporadic ALS some activity, possibly due to the need to remove oxida-
tively damaged proteins (Hyun et al., 2003). Thesecases also express increased levels of the gene for ubi-
quitin-like protein 5. While the function of this protein studies imply that mutant SOD1 can induce oxidative
stress through different mechanisms in manners thatis not known, the high expression nevertheless serves
as an additional indicator that the UPS is affected by are coupled to changes in the UPS system.
In conclusion, the role of protein aggregates in familialthe neurodegenerative process (Ishigaki et al., 2002).
Recent studies employing cultured cells have pro- ALS remains unclear. There is no doubt that aggregates
of SOD1 do exist in a small subset of patients. However,vided additional insight into the effects of mutant SOD1
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as is also the case in other neurodegenerative disorders, Donald, 2000), suggesting that the rate at which the
mutant proteins misfold is related to the length of thesome discussed in this review, the interplay between
polyglutamine tract. A recent study in HD patients hasprotein aggregates, UPS function, and disease patho-
demonstrated that, in the rare instances that patientsgenesis remains an area for exciting and important fu-
are homozygous for the mutation, the rate of diseaseture research.
progression is faster than in the more commonly oc-
curring heterozygous cases (Squitieri et al., 2003). ThisPolyglutamine Diseases: A Family of Mutations,
suggests that protein load may be another importantEach Giving Rise to Specific Lesions
factor in the pathogenesis of polyglutamine disease.and Clinical Features
Protein Aggregate Formation and CompositionThe causative pathological event in the polyglutamine
The polyglutamine disorders exhibit cytoplasmic or in-diseases of the nervous system is a mutation involving
tranuclear protein inclusions, partly composed of amy-a CAG triplet repeat expansion (Gusella and MacDonald,
loid-like fibrils consisting of  strands of the mutant2000). There are a total of nine diseases, and all display
protein (Scherzinger et al., 1997; Ross, 1997). The local-an increased number of glutamine residues in the mutant
ization of the protein aggregates, intranuclear or cyto-protein; however, they differ in their clinical presentation
plasmic, varies between diseases and cells within theand neuropathological profile (Ross, 2002; Taylor et al.,
same disease (Zoghbi and Orr, 2000). Intranuclear ag-2002; Zoghbi and Orr, 2000). Thus, the patients display
gregates have been described for all of the polygluta-different combinations of motor, psychiatric, cognitive,
mine diseases except SCA-2. The events leading to theand sensory symptoms, dependent on which protein
misfolding of expanded polyglutamine-containing pro-exhibits the polyglutamine expansion. Many of these
teins are not fully understood but seem to be partlypatients display onset of symptoms in midlife and a
the result of stochastic processes that require an earlyrelatively slow progression over several years, demon-
nucleation event (Perutz and Windle, 2001) and that arestrating that the disease-associated protein has to be
enhanced by the action of transglutaminase (Kahlem etexpressed for a prolonged period before the nervous
al., 1996). In a second step, the transition from oligomerssystem fails. Although each of these diseases has re-
of misfolded protein to larger intracellular aggregatesceived a great deal of attention from the research com-
appears to involve the microtubule organization centermunity, the most studied CAG triplet repeat disease is
(MTOC or centrosomes) which transports the misfoldedprobably HD. The disease is caused by a mutation in
protein in an orderly fashion to a perinuclear localizationthe gene coding for Huntingtin—a protein of hitherto
(Hoffner et al., 2002; Waelter et al., 2001), akin to theunknown function, although it has been recently impli-
concept of the aggresome as site for accumulation ofcated in the control of gene transcription (Zuccato et
mutant CFTR in CF (Johnston et al., 1998). Several stud-al., 2003). In addition, the family of SCAs (SCA 1, 2, 3,
ies indicate that multiple proteins related to or directly6, 7, and 17), DentatoRubro and PallidoLusyian Atrophy
involved in the UPS are recruited into aggregates of(DRPLA), and SBMA are all characterized by a polyQ
different polyglutamine proteins (Figure 2). They includeexpansion in a specific, disease-related protein. In three
molecular chaperones, the 14-3-3 protein, ubiquitin, en-
cases, the functions of the mutant proteins are known.
zymes involved in ubiquitin conjugation, and both regu-
In SBMA, the expanded polyglutamine is located in the
latory and catalytic subunits of the proteasome (Chai et
androgen receptor (Ross, 2002); in SCA-6, the mutant
al., 1999; Cummings et al., 1998; Schmidt et al., 2002;
protein is part of a voltage-gated calcium channel Stenoien et al., 1999; Stenoien et al., 2002; Verhoef et
(Zoghbi and Orr, 2000); and in SCA-17, it is a TATA al., 2002; Waelter et al., 2001). In addition, other proteins,
box binding protein (Nakamura et al., 2001). With the e.g., SYN (Waelter et al., 2001) and the transcriptional
exception of SBMA, which is X-linked, the neurodegen- cofactor CREB binding protein (CBP) (Jiang et al., 2003),
erative polyglutamine diseases are autosomal-domi- colocalize with the protein inclusions. It is possible that
nant. Therefore, there is strong argument for a toxic gain intranuclear protein inclusions represent a means for
of function of the mutation in most cases. However, a the cell to effectively sequester toxic misfolded proteins,
contribution to the pathogenesis by loss of function of akin to the concept previously mentioned regarding LBs
Huntingtin encoded from the wild-type allele has not in PD, and thereby shield organelles from damage. In
been excluded in HD (Cattaneo et al., 2001), since the this sense, the aggregates in polyglutamine diseases
mutant protein not only aggregates itself but can also would be neuroprotective. Tentative support for this
promote aggregation of the wild-type protein (Busch et idea was obtained in a cell model of HD, where expres-
al., 2003). What all the polyglutamine diseases have in sion of a dominant-negative variant of the E2 Cdc34p
common is that the mutant protein misfolds, and, as decreased the formation of intranuclear inclusions but
discussed below, it often forms protein inclusions. increased the likelihood of cell death (Saudou et al.,
Therefore, it is important to understand why these mu- 1998). In a similar vein, crossing SCA1 mice expressing
tant proteins misfold, how the conformational changes mutant ataxin-1 into a mouse that lacks E6-AP (Ube3a)
mediate toxicity, and in the context of the present re- expression resulted in a reduced number of neurons
view, how the function of UPS is affected. exhibiting intranuclear aggregates (Cummings et al.,
Despite the mutation appearing in different proteins 1999). Interestingly, the expression of the inactive E3
for each disease, the threshold for development of the increased the number of the dying Purkinje cells. It is
pathology is approximately the same, i.e., the existence possible that its wild-type counterpart is somehow in-
of a stretch of 35–45 glutamine residues in the mutant volved in the conjugation of the mutant proteins (al-
protein. The number of CAG repeats is inversely corre- though it has not been shown directly), and the lack of
ubiquitination leads to increased concentration of thelated with the age of disease onset (Gusella and Mac-
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soluble proteins, which is toxic. Ubiquitination in this proteasome due to the presence of the expanded poly-
glutamine stretch and do not allow the entrance of thecase may accelerate precipitation and formation of in-
clusions which may be protective (see above for SYN normal substrates of the proteasome into the complex
(Goellner and Rechsteiner, 2003). In this context, it isin PD).
The Interactions between the UPS and Mutant notable that transglutaminases catalyze the formation
of protease-resistant glutamyl-lysine crosslinks in po-Polyglutamine Proteins
It has been reported that wild-type as well as mutated lyglutamine proteins, making these proteins even less
sensitive to the activity of the proteasome. Formationforms of different disease-related polyglutamine pro-
teins interact directly with elements of the UPS. Thus, of such bonds in proteins have been shown to increase
proteasomal inhibition, possibly by blocking the pore,Huntingtin was found to be ubiquitinated and also to
interact with E2-25 kDa (Kalchman et al., 1996). Similarly, thus enhancing toxicity in cell culture models of DRPLA
(Igarashi et al., 1998) and SBMA (Mandrusiak et al.,Ataxin-7 was found to interact with the S4 subunit of
the proteasome (Matilla et al., 2001). The biological sig- 2003). Administration of cystamine, a transglutaminase
inhibitor, can reduce aggregate formation and death innificance of these interactions is not clear, as substrates
of the UPS typically bind to E3s, and the proteasome cells expressing atrophin-1 (DRPLA model) (Igarashi et
al., 1998) and in cells expressing mutant androgen re-interacts, prior to proteolysis, only with polyubiquiti-
nated proteins or with proteins that shuttle polyubiquiti- ceptor (SBMA model) (Mandrusiak et al., 2003). Similar
effects have been observed using a synthetic fusionnated substrates (except for one established case, that
of ODC; see above). It is possible that these interactions, protein containing GFP and a CAG triplet repeat expan-
sion (de Cristofaro et al., 1999). There are even reportswhile they do not serve to target the substrates for ubi-
quitination/degradation, interfere with the function of claiming that cystamine can reduce transglutaminase
activity in the brain, retard the development of a neuro-the UPS once the mutated proteins are involved. One
case, that of Ataxin-3, deserves special attention (Doss- logical phenotype, and prolong life span in the R6/2
transgenic mouse model of HD (Dedeoglu et al., 2002;Pepe et al., 2003). The protein is found in inclusions
along with the proteasome. It interacts with the human Karpuj et al., 2002), suggesting that transglutaminase
may play an important role in preventing the UPS fromhomolog of Rad23, a cytosolic protein that binds polyu-
biquitinated proteins and is involved, most probably, in clearing polyglutamine expansion-containing proteins.
Crossing R6/1 HD mice onto the background of transglu-shuttling them to the proteasome. In addition, it shares
regions of homology with the proteasome subunit S5a taminase knockout mouse also results in an improved
neurological phenotype and survival, but there is a con-that can recognize polyubiquitinated proteins. It ap-
pears therefore that Ataxin-3 can be a proteasome- comitant increase in the formation of intranuclear pro-
tein aggregates (Mastroberardino et al., 2002).associated factor that may assist in shuttling/binding of
polyubiquitinated proteins and targeting them to the An alternative explanation is that the UPS is over-
whelmed, with rates of formation/delivery of misfoldedproteasome.
What is the evidence that the UPS is functionally inhib- proteins exceeding the capacity of the UPS to tag, tar-
get, and proteolytically degrade them. It has been spec-ited or overwhelmed in cells expressing expanded
polyglutamine proteins? At the outset, it is important to ulated that there may be a relative shortage of ubiquitin
or related enzymes under these conditions. On the otherstress that most studies in this area have been con-
ducted in cultured cells where a truncated form of the hand, it can be argued that the presence of ubiquitin in
the inclusion bodies indicates that the system does notmutant protein has been overexpressed. Both the level
of expression and the length of the protein can have falter at the level of ubiquitination. However, the pres-
ence of ubiquitin in the aggregates does not guaranteesignificant impact on how it affects the UPS, and there-
fore some caution is warranted when extending the find- a functional ubiquitination process, since the polyubi-
quitin chains may not be sufficiently long, for example,ings to the human diseases. An elegant demonstration
that an expanded polyglutamine protein can cause func- to target the misfolded protein molecules to the protea-
some. Also, some of the ubiquitin in the inclusions maytional UPS inhibition was provided by Bence and col-
leagues (Bence et al., 2001). In a cell culture model, they be in its free form, and for ubiquitination to occur, the
inclusions must contain all three conjugating enzymesoverexpressed mutant Huntingtin and observed protea-
somal inhibition accompanied by cell cycle arrest. An- and ATP. In favor of the concept of UPS overload are
reports that demonstrate that protein inclusions fromother study has also demonstrated that UPS inhibition
is only revealed under conditions of increased stress in isolated neurons and brains of transgenic HD mice can
recede within 1 week if the inducible transgene is turnedcells expressing mutant Huntingtin (Ding et al., 2002).
Striatal neurons from R6/2 transgenic HD mice display off (Martin-Aparicio et al., 2001). Their disappearance is
UPS dependent, since the proteasome inhibitor lacta-increased autophagy when they are subjected to oxida-
tive stress (Petersen et al., 2001). Neuronal autophagy cystin prevents the process. In the transgenic mouse,
turning off the transgene is also accompanied by a re-has been found to occur following chronic, low-grade
proteasomal inhibition in cultured neuroblastoma cells covery of the behavioral disease phenotype (Yamamoto
et al., 2000). Additional support for the UPS overload(Ding et al., 2003) and may reflect activation of the lyso-
somal system as cells try to protect themselves during hypothesis comes from studies in R6/2 HD mice. At 9
weeks of age, these mice normally display widespreadstress (Larsen and Sulzer, 2002).
Why should the UPS be functionally inhibited in the Huntingtin aggregates throughout the brain. If oligomeri-
zation of mutant Huntingtin is inhibited by administrationpresence of proteins with an expanded polyglutamine
stretch? One simple explanation is that the mutant pro- of Congo red starting at this age, no aggregates can be
detected in the brain 5 weeks later (Sanchez et al., 2003).teins, unmodifed or following ubiquitination, block the
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In a parallel experiment using a cell culture model, in UPS function may well contribute to the alterations
Congo red was found to increase proteasomal activity in gene transcription in polyglutamine disease (Sugars
in cells expressing a polyglutamine protein but not in and Rubinsztein, 2003). In conclusion, although the pri-
cells expressing a control protein (Sanchez et al., 2003). mary cause of the pathology in polyglutamine diseases
Somewhat contrary to these observations, Dantuma and is clearly defined by the mutation, the actual disease
coworkers have found that only soluble polyglutamine manifestations may also reflect malfunction of the UPS.
proteins are efficiently cleared by the proteasome from Therefore, a better understanding of how the UPS inter-
cultured HeLa cells, and once they are captured in ag- acts with proteins expressing expanded polyglutamine
gregates, they become virtually resistant to proteolysis tracts can lead to the development of therapeutic ap-
(Verhoef et al., 2002). Possibly, the type of cell model proaches.
has some bearing on the results, and the issue of the
activity of the UPS in cells expressing expanded poly- Concluding Remarks
glutamine proteins will require further investigation. As described in this review, rare cases of slowly prog-
Could the functional status of the UPS differ between ressing neurodegenerative diseases, notably PD and
individuals due to genetic or epigenetic influences unre- AD, exhibit aberrations in the UPS that probably play a
lated to the polyglutamine disease, and can this differ- primary and direct role in the disease pathogenesis.
ence play a role in governing the age of disease onset? However, in many others, it appears that inhibition of
The CAG repeat length in the mutant gene accounts for the UPS by the aggregated disease proteins may lead
70% of the variance of age of onset for HD (Becher to a secondary neuronal damage. In a third large group
et al., 1997), and individual differences in UPS activity of neurodegenerative diseases, the linkage between
could influence the time it takes for mutant proteins to UPS impairment and disease pathogenesis is even more
accumulate in the patient’s brain. Interestingly, Li and remote and indirect, if it exists at all. This current state
collaborators demonstrated recently that transgenic HD of knowledge makes it difficult to design mechanism-
mice do not display reduced proteasomal activity in the based therapeutic modalities based on the mode of
brain but rather show a decline in enzyme activity with action of the UPS. In general, it appears that activation
age (Zhou et al., 2003)—similar in both wild-type and of the UPS may have a beneficial effect in many of these
transgenic mice of the same genetic background. Thus,
disorders, yet, it appears that such an activation is hard
the rate of age-related decline in UPS activity could
to achieve. It is possible that once the mediators of
define the efficacy with which the brain handles the
general activation of the system, such as occurs in sep-
mutant proteins and thereby influence the age of onset
sis, muscle atrophy, and cancer-induced cachexia, are
of symptoms in an individual patient.
identified, their selective employment in neurodegener-
There are several possible consequences of the UPS
ative disorders should be examined. Curiously, the onlybeing inhibited in neurons as a result of expression of
drug in the market that targets the UPS and that isexpanded polyglutamine proteins. With our expanding
used to treat multiple myeloma is a potent proteasomeknowledge of the multiple roles of the UPS in a broad
inhibitor. From what we currently know, inhibition of thearray of cellular functions, it will not be surprising to find
proteasome will, most probably, aggravate the pathol-that impairment of the UPS function can be devastating.
ogy and consequently the symptoms of many of theHowever, it can be difficult to dissect out the effects of
known neurodegenerative disorders. The effect ofUPS inhibition from the direct effects of the aggregated
“chemical/pharmacological chaperones” to dissolve theproteins per se and from the toxic effects of oligomers
aggregated proteins cannot be predicted. While certainof mutant polyglutamine proteins. One immediate con-
findings indicate that the soluble proteins are neuro-sequence of inhibition of the UPS in cells expressing a
toxic, alleviation of the inhibition of the UPS may havemutant polyglutamine protein is obviously impairment
beneficial effects. Thus, such agents may have differentin the clearing of misfolded proteins. Consequently, the
effects in different diseases and therefore should beformation of aggregates may increase when the UPS
examined in a systematic manner. Interestingly, suchfails. Lunkes and colleagues demonstrated that trun-
agents are being examined in the treatment of cysticcated Huntingtin, which has undergone proteolytic
fibrosis, where the mutated yet active F508 CFTR iscleavage in the cytoplasm, accumulates more rapidly if
rapidly degraded via the ERAD pathway. The unde-the proteasome is pharmacologically inhibited (Lunkes
graded protein, however, is accumulated in aggre-et al., 2002). This indicates that the truncated fragments
somes. The hope is that some of the dissolved proteinare normally processed via the UPS, and therefore the
will evade ERAD and be expressed at the cell surface.disposal of fragments of mutant proteins will be im-
It appears that a better mechanistic understanding of thepaired. A study in cultured mouse neuroblastoma cells
role that the UPS plays in neurodegeneration is requiredshowed that N-terminal mutant Huntingtin inhibited the
before specific and mechanism-based, rather than gen-20S proteasome catalytic activity, in turn causing im-
eral, modalities can be developed.paired proteasomal degradation of p53, subsequent
loss of mitochondrial membrane potential, release of
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